Imago BioSciences Doses first Patients in the Phase 2a Portion of the Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Imago BioSciences Doses first Patients in the Phase 2a Portion of the Study of IMG-7289 in Acute Myeloid Leukemia and Myelodysplastic Syndrome